Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Adma Biologics (ADMA) Recently Broke Out Above the 20-Day Moving Average
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue?
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ADMA Biologics, Inc. (ADMA) Q2 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brad Tade - Vice President, Financial Operations Conference Call Participants Anthony Petrone - Mizuho Americas Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 08, 2024. At this time, all participants are in a listen-only mode.
Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know
In the latest trading session, Adma Biologics (ADMA) closed at $12.28, marking a +0.82% move from the previous day.
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Adma Biologics (ADMA) closed at $12.18, marking a -1.46% move from the previous day.
